From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in BiopharmaJ&J translational scientist and AI-focused MBA candidate says competitive business training and clinical research demand the same analytical instincts.
Parast, a former DECA national finalist and current biopharma scientist, points to a pattern he has observed firsthand: the analytical rigor demanded by competitive business events, market analysis, financial reasoning, structured problem solving under time pressure, translates directly into the kind of thinking required in clinical pharmacodynamics and biomarker research. "Competitive business events force you to build a defensible argument from incomplete data very quickly," said Parast. "That is not far from what translational science asks of you. You are constantly synthesizing biomarker signals, trial data, and mechanistic biology into a coherent picture, often before every piece of information is in." Parast holds a Bachelor of Science in Biochemistry from Temple University and has contributed to clinical pharmacodynamic research on IL-23 pathway biology in inflammatory diseases, including a 2025 publication in JCI Insight on icotrokinra's pharmacodynamic effects in psoriasis. He is pursuing his MBA at the University of Southern Indiana with a focus on artificial intelligence applications in business, a path he credits partly to the analytical foundation built during his early DECA training. Industry observers have noted a broader trend of pharmaceutical and biotech companies favoring scientific leaders with business fluency, particularly as AI reshapes drug discovery workflows and demands scientists who can speak the language of both R&D and enterprise strategy. Parast's trajectory, from competitive business education to bench science to an AI-focused MBA, reflects that convergence. Learn more at https://roohidparast.github.io Contact: Roohid Parast Science & Fitness 215-372-3397 rparast@its.jnj.com https://roohidparast.github.io End
|
|
Account Phone Number